Eli Lilly yesterday announced the decision to stop ... This decision to cease ongoing Phase III development of the schizophrenia treatment is expected to result in a third-quarter charge to ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

Eli Lilly has reportedly commenced Phase III clinical trials of oral medication, orforglipron, for weight loss in India. The ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to ...

BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...

Eli Lilly has released detailed results from the Phase III QWINT-2 and QWINT-5 trial showing that its once-weekly insulin efsitora (efsitora alfa) demonstrated a similar reduction in HbA1C levels ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

The endorsement follows Eli Lilly's announcement of successful Phase III trial results for its once-weekly insulin efsitora, which is seen as a strong competitor to Novo Nordisk (NYSE:NVO)'s icodec.